Neoadjuvant Serplulimab with S-1 Plus Oxaliplatin Followed by Adjuvant Serplulimab Significantly Improves EFS in PD-L1-positive, Resectable Gastric or GEJ Adenocarcinoma By Ogkologos - June 30, 2026 97 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ASTRUM-006 study Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR EMA Recommends Extension of Therapeutic Indications for Nivolumab and Ipilimumab April 28, 2021 如何在肺癌患病期间和之后维持性健康 November 23, 2022 A bug in the system – the difficulties of linking the... June 2, 2021 Identifying Safer Ways to Look for Recurrence After Testicular Cancer Surgery April 19, 2022 Load more HOT NEWS Police Officer Has Bulletproof Vest to Thank for Helping Her Discover... Ahead of ESMO Immuno-Oncology Congress 2025: topics at a glance ESMO Calls for Robust EU Taxation of Tobacco Products, Aiming to... FOLFIRINOX Improves PFS Compared with Gemcitabine in Patients with Locally Advanced...
